Arrayit is a leading life sciences company providing innovative products and services to empower exploration of the human genome, as well as the genomes of plants and animals. The company’s patented microarray manufacturing platform and proprietary VIP™ genotyping technology are used in a wide variety of research centers around the world – including research laboratories, pharmaceutical businesses, universities, biotechnology firms, hospitals, government agencies and nonprofit research organizations. By developing and commercializing technology that provides novel insights into the function of genes and proteins, Arrayit opens the door for improved disease diagnostics, safer medicines and more nutritional crop plants.
Since 1999, the company has built a powerful portfolio of intellectual property that includes more than 650 life sciences products. In total, Arrayit’s products and services, which are used in the life sciences, pharmaceutical and diagnostics markets, account for an estimated $690 billion in annual revenue. In May, the company built on its strong industry performance by teaming with Vivos on its Global Genome Vault, the only private human DNA vault on Earth. Through this partnership, Arrayit will optimize Vivos’s DNA collection efforts by providing its innovative blood card technology, which allows for the rapid collection, separation, drying and storage of human genomic DNA in a format that is both permanent and highly miniaturized.
“We are pleased to partner with Vivos on this ambitious scientific project,” Rene Schena, chief executive officer of Arrayit, stated in a news release. “Rapid advances in biomedical research offer the promise of future scientific breakthroughs based on high quality archival genomic DNA.”
In recent months, the company has utilized the marketability of its products and services to realize strong financial results. In 2014, Arrayit recorded a 128 percent increase in annual gross profit, demonstrating the immense market potential of its groundbreaking offerings. Look for Arrayit to continue leveraging its diverse product portfolio in the future, providing a platform for sustainable industry growth.
For prospective shareholders, Arrayit’s extensive customer base, which spans more than 50 countries, and innovative portfolio of products and services make the company an intriguing investment opportunity. Look for Arrayit to continue utilizing its proprietary microarray platform in order to expand its market share in the genetic research, pharmaceutical and diagnostic communities moving forward.
For more information, visit www.arrayit.com
